Literature DB >> 19734412

Hypereosinophilic syndrome variants: diagnostic and therapeutic considerations.

Florence Roufosse.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19734412      PMCID： PMC2738708          DOI： 10.3324/haematol.2009.010421

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  29 in total

1.  Resolution of left and right ventricular thrombosis secondary to hypereosinophilic syndrome (lymphoproliferative variant) with reduced intensity conditioning allogenic stem cell transplantation.

Authors:  Juan M Bergua; Elena Prieto-Pliego; Alejandro Román-Barberá; José García-Torón; José Javier Gómez-Barrado; Gonzalo Marcos; Luis López-Gómez; José F Tomás
Journal:  Ann Hematol       Date:  2008-06-03       Impact factor: 3.673

2.  Clonal Th2 cells associated with chronic hypereosinophilia: TARC-induced CCR4 down-regulation in vivo.

Authors:  A de Lavareille; F Roufosse; L Schandené; P Stordeur; E Cogan; M Goldman
Journal:  Eur J Immunol       Date:  2001-04       Impact factor: 5.532

3.  Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome.

Authors:  F Roufosse; L Schandené; C Sibille; K Willard-Gallo; B Kennes; A Efira; M Goldman; E Cogan
Journal:  Br J Haematol       Date:  2000-06       Impact factor: 6.998

4.  Treatment of hypereosinophilic syndrome with imatinib mesilate.

Authors:  Gerald J Gleich; Kristin M Leiferman; Animesh Pardanani; Ayalew Tefferi; Joseph H Butterfield
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

5.  Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study.

Authors:  Georgia Metzgeroth; Christoph Walz; Philipp Erben; Helena Popp; Annette Schmitt-Graeff; Claudia Haferlach; Alice Fabarius; Susanne Schnittger; David Grimwade; Nicholas C P Cross; Rüdiger Hehlmann; Andreas Hochhaus; Andreas Reiter
Journal:  Br J Haematol       Date:  2008-10-17       Impact factor: 6.998

6.  Molecular profiling of CD3-CD4+ T cells from patients with the lymphocytic variant of hypereosinophilic syndrome reveals targeting of growth control pathways.

Authors:  Marie Ravoet; Catherine Sibille; Chunyan Gu; Myriam Libin; Benjamin Haibe-Kains; Christos Sotiriou; Michel Goldman; Florence Roufosse; Karen Willard-Gallo
Journal:  Blood       Date:  2009-07-16       Impact factor: 22.113

7.  Treatment of patients with the hypereosinophilic syndrome with mepolizumab.

Authors:  Marc E Rothenberg; Amy D Klion; Florence E Roufosse; Jean Emmanuel Kahn; Peter F Weller; Hans-Uwe Simon; Lawrence B Schwartz; Lanny J Rosenwasser; Johannes Ring; Elaine F Griffin; Ann E Haig; Paul I H Frewer; Jacqueline M Parkin; Gerald J Gleich
Journal:  N Engl J Med       Date:  2008-03-16       Impact factor: 91.245

8.  Airway eosinophils: allergic inflammation recruited professional antigen-presenting cells.

Authors:  Hai-Bin Wang; Ionita Ghiran; Klaus Matthaei; Peter F Weller
Journal:  J Immunol       Date:  2007-12-01       Impact factor: 5.422

9.  T-cell abnormalities are present at high frequencies in patients with hypereosinophilic syndrome.

Authors:  Grzegorz Helbig; Agata Wieczorkiewicz; Joanna Dziaczkowska-Suszek; Miroslaw Majewski; Slawomira Kyrcz-Krzemien
Journal:  Haematologica       Date:  2009-09       Impact factor: 9.941

10.  Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing.

Authors:  Amy D Klion; Jamie Robyn; Irina Maric; Weiming Fu; Laura Schmid; Steven Lemery; Pierre Noel; Melissa A Law; Marilyn Hartsell; Cheryl Talar-Williams; Michael P Fay; Cynthia E Dunbar; Thomas B Nutman
Journal:  Blood       Date:  2007-08-20       Impact factor: 22.113
View more
  19 in total

1.  Antibodies to watch in 2010.

Authors:  Janice M Reichert
Journal:  MAbs       Date:  2010-01-16       Impact factor: 5.857

2.  Idiopathic hypereosinophilic syndrome: a new cause of vasculitis of the central nervous system.

Authors:  C M Rice; K M Kurian; S Renowden; A Whiteway; C Price; N J Scolding
Journal:  J Neurol       Date:  2015-04-07       Impact factor: 4.849

3.  Asymptomatic circulating T-cell clone cause renal polymorphic inflammatory fibrosis.

Authors:  David Ribes; Audrey Casemayou; Hélène El Hachem; Camille Laurent; Céline Guilbeau-Frugier; François Vergez; Suzanne Tavitian; Joost P Schanstra; Dominique Chauveau; Jean-Loup Bascands; Loïc Ysebaert; Stanislas Faguer
Journal:  Clin Exp Nephrol       Date:  2016-12-26       Impact factor: 2.801

Review 4.  Clinical overview of cutaneous features in hypereosinophilic syndrome.

Authors:  Sabine Gisela Plötz; Bettina Hüttig; Birgit Aigner; Christian Merkel; Knut Brockow; Cezmi Akdis; Ulf Darsow; Johannes Ring
Journal:  Curr Allergy Asthma Rep       Date:  2012-04       Impact factor: 4.806

5.  Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study.

Authors:  Andreas Hochhaus; Philipp D le Coutre; Hagop M Kantarjian; Michele Baccarani; Philipp Erben; Andreas Reiter; Tracey McCulloch; Xiaolin Fan; Steven Novick; Francis J Giles
Journal:  J Cancer Res Clin Oncol       Date:  2013-09-22       Impact factor: 4.553

6.  Suspected "t-cell-mediated" hypereosinophilic syndrome presenting with cerebral watershed infarcts.

Authors:  S Dujardin; R Schots; S De Raedt
Journal:  Case Rep Neurol Med       Date:  2011-11-29

Review 7.  Hypereosinophilic Syndrome.

Authors:  Casey Curtis; Princess Ogbogu
Journal:  Clin Rev Allergy Immunol       Date:  2016-04       Impact factor: 10.817

8.  The identification of eosinophilic gastroenteritis in prednisone-dependent eosinophilic bronchitis and asthma.

Authors:  Parameswaran Nair; Sergei I Ochkur; Cheryl Protheroe; Elizabeth Simms; Nancy A Lee; James J Lee
Journal:  Allergy Asthma Clin Immunol       Date:  2011-03-01       Impact factor: 3.406

9.  The lymphoid variant of hypereosinophilic syndrome: study of 21 patients with CD3-CD4+ aberrant T-cell phenotype.

Authors:  Guillaume Lefèvre; Marie-Christine Copin; Delphine Staumont-Sallé; Martine Avenel-Audran; Hélène Aubert; Alain Taieb; Gilles Salles; Hervé Maisonneuve; Kamel Ghomari; Félix Ackerman; Fanny Legrand; André Baruchel; David Launay; Louis Terriou; Christian Leclech; Chahera Khouatra; Chafika Morati-Hafsaoui; Myriam Labalette; Raphäel Borie; François Cotton; Noémie Le Gouellec; Franck Morschhauser; Jacques Trauet; Catherine Roche-Lestienne; Monique Capron; Pierre-Yves Hatron; Lionel Prin; Jean-Emmanuel Kahn
Journal:  Medicine (Baltimore)       Date:  2014-10       Impact factor: 1.889

10.  Dominant Role of CD80-CD86 Over CD40 and ICOSL in the Massive Polyclonal B Cell Activation Mediated by LAT(Y136F) CD4(+) T Cells.

Authors:  Stéphane Chevrier; Céline Genton; Bernard Malissen; Marie Malissen; Hans Acha-Orbea
Journal:  Front Immunol       Date:  2012-02-24       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.